Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Molecular Partners News

    3,26 CHF -4,54% -0,155 CHF
    In : 3,3305 € | 24.04.24 17:31:51 SIX Swiss Exchange aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A12DEH
    ISIN: CH0256379097
    US-Symbol: MLLCF
    Typ: Aktie

    Molecular Partners News

    19.04.24 - GlobeNewswire
    Life Science Cares Launches in Switzerland
    First international chapter of Life Science Cares established in Switzerland – bringing hearts and minds together by empowering the life sciences industry to support local communities
    10.01.22 - Der Aktionär
    Pfizer und Merck & Co aufgepasst: Neues Corona‑Mittel in den Startlöchern
    15.06.21 - ACCESSWIRE
    Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company developing a new class of custom-...
    13.06.21 - ACCESSWIRE
    Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep
    Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the ...
    09.06.21 - ACCESSWIRE
    Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 9, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company developing a new class of custom-​built ...
    27.05.21 - Börse Online
    Newsticker Corona: Schweden kündigt Lockerungen an
    Es folgen aktuelle Entwicklungen rund um die Virus-​Pandemie: Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.
    27.05.21 - Der Aktionär
    Dividendenperle Novartis: Hoffnung für Corona‑Patienten – wichtige Studie
    27.05.21 - Börse Online
    Newsticker Corona: Dreyer warnt vor übereilter Entscheidung zur Impfung von Kindern
    Es folgen aktuelle Entwicklungen rund um die Virus-​Pandemie: Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.
    27.05.21 - ACCESSWIRE
    Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
    EMPATHY global multi-​center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll ...
    06.05.21 - ACCESSWIRE
    Molecular Partners' COVID-19 Antiviral Candidate, Ensovibep, Maintains Potent Neutralization Against Emerging Viral Variants In Vitro
    In Vitro Studies Show Ensovibep (MP0420) Maintains Full Potency Against the Known Mutations of SARS-CoV-2, Including Those Present in Variants First Identified in Brazil, ...
    04.05.21 - ACCESSWIRE
    Interim Management Statement Q1 2021: Major Advances in COVID-19 Program, Continued Progress in Oncology Pipeline
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 4, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company developing a new class of custom-​built ...
    23.04.21 - ACCESSWIRE
    Molecular Partners Files Registration Statement for Proposed Initial Public Offering in the United States
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 23, 2021 /  Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company that is developing a new class of ...
    21.04.21 - ACCESSWIRE
    Shareholders of Molecular Partners AG Approve all Board Proposals at the Annual General Meeting; Agnete Fredriksen and Dominik Höchli Elected New Board Members
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / April 21, 2021 / At today's AGM of Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company developing a new ...
    10.04.21 - ACCESSWIRE
    Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR
    Data support potential of DARPin® CD3 T-cell engager candidate for improved safety window while limiting tumor escape New data show that the FAP x CD40 product candidate, ...
    06.04.21 - ACCESSWIRE
    Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
    First Study of Ensovibep in Patients With Symptomatic COVID-19 Disease Designed To Evaluate Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep ...
    25.03.21 - ACCESSWIRE
    Molecular Partners Nominates Dominik Höchli, M.D., for Election to Its Board of Directors
    Pharmaceutical industry expert with extensive knowledge of R&D and commercialization
    22.03.21 - ACCESSWIRE
    Molecular Partners Announces Intention to Conduct a Registered Offering in the United States
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 22, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company that is developing a new class of ...
    15.03.21 - ACCESSWIRE
    Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral Candidate, ensovibep, in NIH-Sponsored ACTIV-3 Trial
    ACTIV-3 trial planned to investigate safety and efficacy of ensovibep in adults hospitalized with a COVID-19 diagnosis; first patient dose expected in Q2 2021 Ensovibep to be first ...
    11.03.21 - ACCESSWIRE
    Molecular Partners Nominates Agnete Fredriksen for Election to Its Board of Directors
    Acknowledged innovation leader with deep scientific and business expertise in immunotherapy, oncology and infectious diseases
    10.03.21 - ACCESSWIRE
    Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting
    ZURICH-​SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-​stage biotech company that is developing a new class of ...

    Newssuche

    Videos

    newspaper
    24.04.24
    Technical Trading: AUD/USD mit Mega Chance
    AUD/USD Long Typ: Turbo Open End WKN: UM0EHU Hebel: 6,42 Laufzeit: OpenEnd Einstieg: Market ... Mehr »